Are iFNα and its response proteins , IP-10 and SIGLEC-1 , biomarkers of disease activity in systemic lupus erythematosus?
IFNα, IP-10 and SIGLEC-1 emerged as beneficial biomarkers of DA in patients with SLE. Therefore the implementation of IFN biomarkers in standard lupus diagnostics should be reappraised, especially in view of emerging anti-IFN-directed therapies.
The study amifostine regimen did not reduce the toxicity or activity of the FC regimen in patients with CLL.